Michel was a postdoctoral researcher at the University Hospital Zurich’s Infectious Diseases Department, responsible for the execution of the clinical part of the Swiss National Foundation-backed study "Development of a real-time biosensing system of SARS-CoV-2 to improve healthcare workers safety during COVID-19 pandemics".
During his time at the Swiss Army, he was a Lead Physician for the organization, planning, and implementation of a nationwide mass testing for COVID-19 of 14,000 recruits. He co-lead a prospective cohort study involving 550 patients evaluating infectivity of COVID-19 resulting in multiple publications and mentions by Reuters and the New York Times.
In 2020, Michel was appointed Chief Medical Officer at NATO’s peace-keeping mission in Kosovo. Prior to Testasy, Michel co-founded GobiX GmbH, a Swiss medical company using 3D printing technologies. GobiX addressed the shortage of testing swabs in Europe during the COVID-19 pandemic, and its 3D-printed testing swabs were quickly picked up by the Swiss Armed Forces.
In 2021, together with Jeyla Sadikova, Michel started GobiX’ Testasy brand as a pilot project in Warsaw, Poland. Testasy offered Europe’s first fully digital COVID-19 testing and certification product, mainly targeted at travellers. Following a rapid increase in demand, Testasy was launched in Switzerland, where it became exponentially successful. The startup then launched in the UK and Estonia.
Michel holds a degree in Master in Public Health and Epidemiology from Harvard Chan School of Public Health.
Jeyla began her career at BP’s Procurement department where she managed several multi-billion dollar drilling contracts, working with engineers, audit and financial controllers. During her short tenure at BP, she also set up a Power BI-backed KPI system which was later adopted by all of the company’s global procurement departments.
Jeyla joined McKinsey in 2018. Her projects include:
In 2021, she co-founded Testasy alongside Michel, acting as the company’s CCO and COO. With an initial investment of CHF30,000, Testasy generated a six-figure income from April to December 2021. Testasy also became a partner of choice for Abbott Pharmaceuticals in Europe, and had McKinsey and the Swiss National Television among its clients. Jeyla holds a Masters degree in Strategy from Imperial College London. Jeyla is the Vice President of Hack4Health Foundation, bringing Swiss healthcare to communities in need worldwide. It has provided over 200 tons of medical aid to Ukraine, as well as free tailored telemedical solutions and educational material.
Loup has a background in mathematics and systems engineering, currently finishing his Masters degree at the Zurich University of Applied Sciences (ZHAW).
His professional career has spanned several roles, including engineering and cybersecurity consulting at EY.
Loup is a space and astronomy enthusiast, and a leader of Swiss Federal Institute of Technology in Lausanne (EPFL) Rocket Team, in charge of developing, planning and implementing experiments. Some of those include a life sensor for space exploration using a non-optic microscope and custom software to nano-movements of living organisms, and a 3D printed mechanism that harvests vibrations and converts them into electricity using piezo elements.
Loup is a recipient of multiple scientific awards, including European Rocketry Challenge Award and Jim Furfaro Award of Spaceport America Cup for technical excellence.
Loup’s non-optic life sensor used in his space experiments is the basis for Illumicell’s hardware component.
At the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, he developed AI-driven tools to support the early diagnosis of cognitive disorders. His projects have spanned several medical specialties and were shaped through close collaboration with world-renowned physicians, giving him deep insight into clinical needs and how to embed AI effectively into routine medical practice.
His work at USZ and CHUV, both consistently ranked among the world’s leading hospitals, reflects a unique ability to bridge advanced technology and frontline healthcare, ensuring that AI solutions are both impactful and clinically meaningful.
Javier holds a PhD in Physics and Nuclear Engineering from CERN and the Universitat Politècnica de Catalunya. Following his PhD, he was selected for the highly competitive COFUND Fellowship at CERN, awarded to top international researchers. During this fellowship, he supervised operations at a key particle accelerator facility and contributed to work for the Large Hadron Collider (LHC) – one of the world’s most ambitious and high-profile scientific endeavors.
He has collaborated with leading institutions including the Swiss National Supercomputing Centre (CSCS), the ETH AI Center, Innosuisse and the Swiss Data Science Center to develop and scale innovative technologies in healthcare. His expertise spans artificial intelligence, cloud infrastructure, high-performance computing and scientific data visualization, enabling the delivery of robust, efficient, and clinically meaningful solutions at the intersection of medicine, science, and technology.
Combining deep scientific expertise with frontline clinical experience, Javier brings a unique perspective to healthcare innovation. As a project lead, he has guided multidisciplinary teams across hospitals, academia, and industry to translate AI research into real-world clinical solutions. His ability to align technical development with clinical priorities ensures that the solutions he delivers are not only technically sound and clinically relevant, but also strategically impactful in driving digital transformation in healthcare.
His expertise spans electromechanical devices, surgical robotics, and multispectral imaging technologies.
As part of J&J's orthopedics robotics team, Robert helped launch the Velsy Knee platform, led the systems engineering development of a future spine surgery robot, and conducted technical due diligence on external technologies. As Director of Product Engineering at Precision Healing, Robert led a multispectral imaging camera for chronic wound imaging from initial prototype to FDA 510(k) clearance.
Most recently, he's been working with and advising a number of MedTech startups through different stages of the product development process.
At ETH Zurich, Anna engaged in diverse projects at the intersection of Optics, Quantum Physics, and Solid-State Physics. Her primary academic achievement was the theoretical description, modeling, and experimental realization of few-atom-thick light-emitting devices based on a novel type of electron tunneling.
After completing her Ph.D., Anna wanted to apply her knowledge in Physics to the Medical Technology domain and joined illumicell AI AI as an Optical Engineer. As a member of the Tech Team, she contributes to the development of a novel cell scanner and image processing algorithms, overlooking the R&D trajectory of the Team.
His training began at Harvard University where he graduated summa cum laude with a degree in Human Developmental and Regenerative Biology. After college, Austin worked as a consultant leveraging data-driven insights for hospitals, pharmaceutical companies, and insurance providers to gain a broader understanding of the healthcare delivery space.
He then pursued his medical degree at the University of California, San Francisco (UCSF). While at UCSF, Austin spent a summer as an AUA Urology Care Foundation Summer Medical Student Fellow working on a mobile application to optimize lower urinary tract symptom and tamsulosin side effect tracking in elderly men with BPH.
Mahmoud is an accomplished scientist specializing in disease phenotyping through advanced microscopy and multi-omics technologies. With over 15 years of combined academic and industry experience, he has deep expertise in microbiology, metabolomics, cell and molecular biology, and bioinformatics.
He holds a Ph.D. in Bioanalytical Chemistry from Saint Louis University, where his exceptional research earned him the Outstanding Ph.D. Chemistry Student Award and the Alpha Sigma Nu Award, among other honors. His work has been widely recognized, including a Research Excellence Award at the 2023 International Symposium on Microscale Bioseparations, a Best Poster Award at the same conference in 2021, and features in high-impact journals such as Wiley’s top-cited publications for 2021–2022.
